Veeva put AI agents on 200 pharma customers ahead of a December 2029 deadline, with no price named
Vault CRM passed 200 live customers and Novo is queued for the agents. The bill lands at renewal, on a base with little choice but to move, before legacy CRM support ends in December 2029.
Vincent Jiang · 3 min read
Veeva+3.97% — Veeva, up 3.97 percent today spent the first half of October handing pharma its agentic future. More than 200 customers are now live on Vault CRM, with GSK, Ionis, Corcept and Novo among them 1. The named leaders are deploying the Agentic Call Report, the first agent product out of the gate 1.
Novo is going further. Frank Armenante, Novo's director of field systems, says his team will use the new Agentic Call Reporting and the Media Agent, and that Veeva will "make that simple for us" 1. Next week's R&D and Quality Summit in Boston, October 20 to 21, puts Veeva Falcon and Vault AI on stage in front of more than 2,500 life-sciences buyers 2.
A deadline is doing the selling
The migration keeps compounding: 125 customers live in March 3, more than 180 at the August quarter with 12 of the top 20 biopharmas committed 4, Amgen choosing a global rollout in September 5, and 200-plus now 1.
Vault CRM went from 125 live customers to 200-plus in seven months
Data
| Value | |
|---|---|
| March 2026 | 125+ |
| August 2026 | 180+ |
| October 2026 | 200+ |
Veeva has already pulled end-of-support for legacy Veeva CRM forward, from September 2030 to the end of December 2029 3. It serves more than 1,500 customers, 175-plus of them emerging biotechs on Veeva Basics 6, and management says it is confident of keeping more than 70% of the life-sciences CRM market 5. The agents ride in on top of that base, and a price list would only slow the deadline down.
Falcon arrives in November, still unpriced
Falcon, announced in May as Veeva's "first offering in agentic labor," reaches its five early adopters next month 47. Falcon Router followed in September, also without a number attached 8. Veeva claims its tools can cut certain manual tasks by up to 70% 9. Savings are quantified; the bill is not.
The stock outran the Street's own targets
Q2 revenue was $928.0 million, up 18%, and full-year guidance rose to between $3,682 and $3,687 million, with non-GAAP EPS near $9.21 4. Shares jumped as much as 20.9% the day after 10. On October 9 the stock opened at $296.15, above the $284.88 consensus target from 28 analysts 11.
Revenue re-accelerated to 17.6% growth, Veeva's fastest since spring 2024
Data
| Total revenue | |
|---|---|
| Q1 '24 | $0.65B |
| Q2 '24 | $0.68B |
| Q3 '24 | $0.7B |
| Q4 '24 | $0.72B |
| Q1 '25 | $0.76B |
| Q2 '25 | $0.79B |
| Q3 '25 | $0.81B |
| Q4 '25 | $0.84B |
| Q1 '26 | $0.88B |
| Q2 '26 | $0.93B |
The bulls still hold three named targets above the price, led by Wells Fargo's $330, and count 14 of the top 20 biopharmas committed, against management's $6 billion run-rate goal for 2030 9. The quieter signal: insiders sold 51,591 shares worth $13.36 million in 90 days, including a 38.7% cut to EVP Daniel Rizzo's stake on October 2, disclosed as tax-withholding related 11.
At $296, Veeva clears its consensus target; only three named targets sit above it
- Estimate
Data
| Value | |
|---|---|
| Wells Fargo (1 Oct) (estimate) | $330 |
| Needham (27 Aug) (estimate) | $310 |
| Baird (27 Aug) (estimate) | $300 |
| VEEV share price, 9 Oct open | $296.15 |
| UBS (27 Aug) (estimate) | $290 |
| Consensus, 28 analysts (estimate) | $284.88 |
| Morgan Stanley (27 Aug) (estimate) | $275 |
| Citigroup (28 Aug) (estimate) | $273 |
| Evercore ISI (Oct) (estimate) | $250 |
Watch Boston for the first dollar figure
Falcon's early adopters go live in November 7. Every renewal after that is where the price of agentic labor finally gets set, and nothing published yet says what it is.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
